- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Patent holdings for IPC class A61P 25/28
Total number of patents in this class: 20153
10-year publication summary
|
655
|
695
|
1128
|
1507
|
1506
|
1660
|
1892
|
1924
|
1597
|
822
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Mondobiotech Laboratories AG | 311 |
278 |
| The Regents of the University of California | 19868 |
258 |
| F. Hoffmann-La Roche AG | 7929 |
245 |
| Takeda Pharmaceutical Company Limited | 2711 |
162 |
| Hoffmann-La Roche Inc. | 3405 |
152 |
| The General Hospital Corporation | 4720 |
120 |
| Eisai R&D Management Co., Ltd. | 1238 |
120 |
| Janssen Pharmaceutica N.V. | 3399 |
119 |
| H. Lundbeck A/S | 1234 |
106 |
| Novartis AG | 10867 |
105 |
| AstraZeneca AB | 2917 |
105 |
| Eli Lilly and Company | 3834 |
103 |
| The Johns Hopkins University | 5659 |
96 |
| AC Immune S.A. | 260 |
93 |
| Centre National de La Recherche Scientifique | 10414 |
92 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3367 |
89 |
| Bristol-myers Squibb Company | 4878 |
76 |
| Genentech, Inc. | 3975 |
74 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 2804 |
69 |
| Ramot at Tel-Aviv University Ltd. | 1474 |
68 |
| Other owners | 17623 |